Clinical trial · Interventional
TAURINE and HCC PATIENTS
COMPARISON BETWEEN SERUM TAURINE AND SPECIFIC TUMOR MARKERS FOR EARLY DETECTION AND DIAGNOSIS OF HCC IN EGYPTIAN PATIENTS
NCT04193761CI-TRIAL-00042151completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Serum taurine level beside (AFP and AFU) are of great value in early diagnosis in HCC Egyptian patients and may have a rule in identifying end-stage liver disease (ESLD) patients candidate for LDLT.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Taurine in HCC | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| taurine level | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- Control
- interventionNames
- Diagnostic Test: taurine level
- type
- ACTIVE_COMPARATOR
- label
- Chronic hepatitis
- interventionNames
- Diagnostic Test: taurine level
- type
- ACTIVE_COMPARATOR
- label
- Cirrhosis
- interventionNames
- Diagnostic Test: taurine level
- type
- ACTIVE_COMPARATOR
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Chronic hepatitis * Cirrhosis * HCC patients Exclusion Criteria: * Patient refusal * Bleeding tendency * Tense ascites * Inability to obtain a liver biopsy
References
Publications (0)
Data not yet available
No reference posted for this study.